文献速递浆细胞疾病

Bcl-2家族异质性调控与药物外排介导多发性骨髓瘤MCL-1抑制剂耐药

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma.
PubMed 文献 · Blood Adv · 2021-01-01

该研究探讨多发性骨髓瘤对MCL-1抑制剂的获得性耐药机制及优化策略。发现耐药途径异质,涉及促凋亡与抗凋亡Bcl-2家族蛋白基线改变及BH3谱依赖的复合物形成。高通量药物筛选(n=528)提示替代BH3模拟物(Bcl-xL>Bcl-2抑制)为最佳联合伙伴,而传统药物类多拮抗。基质支持降低MCL-1抑制剂活性,可被Bcl-xL或Bcl-2抑制克服;卡非佐米耐药细胞存在Bcl-2家族失调和MDR1驱动外排导致的交叉耐药。

要点

  • MCL-1抑制剂耐药途径异质,涉及Bcl-2家族蛋白基线改变和BH3谱依赖的复合物形成。
  • 替代BH3模拟物(Bcl-xL>Bcl-2抑制)是MCL-1抑制剂的最佳联合伙伴,传统药物多拮抗。
  • 基质支持降低MCL-1抑制剂活性,可被Bcl-xL或Bcl-2抑制克服;MDR1外排介导交叉耐药。

核心结论

  • 多发性骨髓瘤对MCL-1抑制剂的获得性耐药由Bcl-2家族异质性调控和MDR1驱动药物外排共同介导。
  • 替代BH3模拟物(优先抑制Bcl-xL)是MCL-1抑制剂在敏感和耐药细胞中的最佳联合伙伴。

研究设计与样本

  • 研究探索多发性骨髓瘤获得性MCL-1抑制剂耐药机制及优化策略。
  • 采用无偏倚高通量药物筛选(n=528)评估联合伙伴。
  • 使用卡非佐米耐药细胞模型研究交叉耐药。

主要发现

  • 耐药途径异质,涉及促凋亡(BAK、BAX、BIM)和抗凋亡(Bcl-2、MCL-1)蛋白基线改变。
  • 耐药表现取决于亲本细胞BH3谱,引导Bcl-2:BIM增强形成和/或治疗诱导的Bcl-xL:BIM及Bcl-xL:BAK复合物动态形成。
  • 高通量药物筛选(n=528)显示替代BH3模拟物(Bcl-xL>Bcl-2抑制)为顶级联合伙伴,传统药物类(如抗有丝分裂剂)主要拮抗。
  • 基质支持降低MCL-1抑制剂活性(药物类效应),并发Bcl-xL或Bcl-2抑制可克服。
  • 卡非佐米耐药细胞显示异质性Bcl-2家族失调和MCL-1抑制剂交叉耐药,与MDR1驱动外排相关。

临床怎么用

  • 临床需采用患者适配的治疗方案,并追踪肿瘤和/或克隆特异性对MCL-1抑制的适应。
  • MCL-1抑制剂联合替代BH3模拟物(优先抑制Bcl-xL)可能优化疗效。
  • 在基质支持下需考虑联合Bcl-xL或Bcl-2抑制以克服耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antiapoptotic Bcl-2 family members have recently (re)emerged as key drug targets in cancer, with a tissue- and tumor-specific activity profile of available BH3 mimetics. In multiple myeloma, MCL-1 has been described as a major gatekeeper of apoptosis. This discovery has led to the rapid establishment of clinical trials evaluating the impact of various MCL-1 inhibitors. However, our understanding about the clinical impact and optimal use of MCL-1 inhibitors is still limited. We therefore explored mechanisms of acquired MCL-1 inhibitor resistance and optimization strategies in myeloma. Our findings indicated heterogeneous paths to resistance involving baseline Bcl-2 family alterations of proapoptotic (BAK, BAX, and BIM) and antiapoptotic (Bcl-2 and MCL-1) proteins. These manifestations depend on the BH3 profile of parental cells that guide the enhanced formation of Bcl-2:BIM and/or the dynamic (ie, treatment-induced) formation of Bcl-xL:BIM and Bcl-xL:BAK complexes. Accordingly, an unbiased high-throughput drug-screening approach (n = 528) indicated alternative BH3 mimetics as top combination partners for MCL-1 inhibitors in sensitive and resistant cells (Bcl-xL>Bcl-2 inhibition), whereas established drug classes were mainly antagonistic (eg, antimitotic agents). We also revealed reduced activity of MCL-1 inhibitors in the presence of stromal support as a drug-class effect that was overcome by concurrent Bcl-xL or Bcl-2 inhibition. Finally, we demonstrated heterogeneous Bcl-2 family deregulation and MCL-1 inhibitor cross-resistance in carfilzomib-resistant cells, a phenomenon linked to the MDR1-driven drug efflux of MCL-1 inhibitors. The implications of our findings for clinical practice emphasize the need for patient-adapted treatment protocols, with the tracking of tumor- and/or clone-specific adaptations in response to MCL-1 inhibition.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bolomsky A, Miettinen JJ, Malyutina A, et al. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Adv. 2021. PMID: 34478517. doi:10.1182/bloodadvances.2020003826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。